Products for Research Use Only

CTOP (TFA)

CAT: 0804-HY-P1329ASize: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P1329ASize:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity[1][2].
UNSPSC
12352209
Target
Opioid Receptor
Type
Peptides
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ctop-tfa.html
Purity
99.84
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
OC(C(F)(F)F)=O.O=C(N[C@@H]1CC2=CNC3=CC=CC=C23)[C@H](CC4=CC=C(O)C=C4)NC([C@@H](NC([C@@H](CC5=CC=CC=C5)N)=O)CSSC([C@@H](C(N[C@@H]([C@@H](C)O)C(N)=O)=O)NC([C@]([H])([C@@H](C)O)NC([C@H](CCCN)NC1=O)=O)=O)(C)C)=O.[x]
Molecular Formula
C50H67N11O11S2.xC2HF3O2
Molecular Weight
1062.27 (free base)
References & Citations
[1]Gulya K, et al. Central effects of the potent and highly selective μ opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice. Eur J Pharmacol. 1988 Jun 10;150 (3) :355-60.|[2]Badiani A, et al. Intra-VTA injections of the mu-opioid antagonist CTOP enhance locomotor activity. Brain Res. 1995 Aug 28;690 (1) :112-6.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
μ Opioid Receptor/MOR